| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community Health Services | 10 | 2018 | 650 | 1.450 |
Why?
|
| Haiti | 28 | 2022 | 553 | 1.350 |
Why?
|
| HIV Infections | 38 | 2018 | 16715 | 1.210 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 17 | 2023 | 912 | 1.020 |
Why?
|
| International Cooperation | 8 | 2020 | 1419 | 0.940 |
Why?
|
| Rural Population | 15 | 2022 | 2207 | 0.940 |
Why?
|
| Antitubercular Agents | 16 | 2023 | 1320 | 0.920 |
Why?
|
| Fluorine Radioisotopes | 9 | 1999 | 443 | 0.800 |
Why?
|
| Lesotho | 9 | 2023 | 70 | 0.750 |
Why?
|
| Resource Allocation | 2 | 2020 | 341 | 0.750 |
Why?
|
| Public Policy | 2 | 2022 | 572 | 0.740 |
Why?
|
| Health Planning Organizations | 1 | 2019 | 12 | 0.700 |
Why?
|
| Medical Assistance | 1 | 2020 | 104 | 0.690 |
Why?
|
| Refugees | 3 | 2022 | 511 | 0.660 |
Why?
|
| Leiomyoma | 2 | 2022 | 730 | 0.660 |
Why?
|
| Organizational Objectives | 2 | 2019 | 438 | 0.650 |
Why?
|
| Anti-HIV Agents | 13 | 2018 | 4255 | 0.650 |
Why?
|
| Monoamine Oxidase Inhibitors | 4 | 1999 | 157 | 0.650 |
Why?
|
| Social Support | 8 | 2016 | 2118 | 0.650 |
Why?
|
| Health Services Accessibility | 13 | 2022 | 5136 | 0.640 |
Why?
|
| Monoamine Oxidase | 4 | 1999 | 178 | 0.640 |
Why?
|
| Delivery of Health Care | 10 | 2023 | 5319 | 0.630 |
Why?
|
| Developing Countries | 14 | 2020 | 2815 | 0.610 |
Why?
|
| Directly Observed Therapy | 8 | 2018 | 137 | 0.610 |
Why?
|
| Health Plan Implementation | 2 | 2021 | 351 | 0.590 |
Why?
|
| Population Growth | 1 | 2016 | 52 | 0.570 |
Why?
|
| Tuberculosis, Pulmonary | 6 | 2014 | 811 | 0.560 |
Why?
|
| Birth Rate | 1 | 2016 | 170 | 0.520 |
Why?
|
| Child Mortality | 3 | 2014 | 198 | 0.510 |
Why?
|
| Human Rights | 4 | 2022 | 307 | 0.510 |
Why?
|
| Rural Health | 3 | 2006 | 305 | 0.510 |
Why?
|
| Hemorrhagic Fever, Ebola | 2 | 2016 | 426 | 0.490 |
Why?
|
| Tomography, Emission-Computed | 11 | 1999 | 1143 | 0.450 |
Why?
|
| Community Health Planning | 1 | 2013 | 165 | 0.440 |
Why?
|
| Communicable Disease Control | 5 | 2020 | 856 | 0.430 |
Why?
|
| Caregivers | 4 | 2015 | 2098 | 0.430 |
Why?
|
| Receptors, Dopamine D2 | 5 | 1999 | 475 | 0.420 |
Why?
|
| Maternal Welfare | 1 | 2012 | 115 | 0.410 |
Why?
|
| Anti-Retroviral Agents | 5 | 2012 | 1714 | 0.400 |
Why?
|
| Uterine Neoplasms | 1 | 2021 | 1513 | 0.390 |
Why?
|
| Medication Adherence | 4 | 2018 | 2063 | 0.390 |
Why?
|
| Health Priorities | 3 | 2020 | 380 | 0.390 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2010 | 27 | 0.380 |
Why?
|
| Women's Rights | 1 | 2011 | 69 | 0.380 |
Why?
|
| Fluoxetine | 3 | 1999 | 749 | 0.360 |
Why?
|
| Poverty Areas | 3 | 2006 | 275 | 0.360 |
Why?
|
| Sierra Leone | 4 | 2024 | 166 | 0.350 |
Why?
|
| Rural Health Services | 6 | 2014 | 380 | 0.350 |
Why?
|
| HIV | 3 | 2013 | 1604 | 0.350 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2011 | 1320 | 0.340 |
Why?
|
| Public Health | 1 | 2022 | 2603 | 0.330 |
Why?
|
| Civil Disorders | 1 | 2008 | 8 | 0.320 |
Why?
|
| HIV Seropositivity | 4 | 2014 | 971 | 0.310 |
Why?
|
| Harm Reduction | 1 | 2009 | 129 | 0.310 |
Why?
|
| Reproductive Medicine | 1 | 2009 | 108 | 0.300 |
Why?
|
| Poverty | 10 | 2021 | 2660 | 0.300 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2010 | 2232 | 0.290 |
Why?
|
| Blood Specimen Collection | 1 | 2008 | 246 | 0.290 |
Why?
|
| Humans | 110 | 2024 | 743811 | 0.290 |
Why?
|
| Maternal Health Services | 1 | 2012 | 455 | 0.290 |
Why?
|
| Antiretroviral Therapy, Highly Active | 10 | 2012 | 1872 | 0.290 |
Why?
|
| Primary Health Care | 4 | 2022 | 4556 | 0.280 |
Why?
|
| Rwanda | 9 | 2018 | 703 | 0.280 |
Why?
|
| Tuberculosis | 6 | 2023 | 1914 | 0.280 |
Why?
|
| Narration | 1 | 2008 | 212 | 0.280 |
Why?
|
| Adolescent Behavior | 2 | 2015 | 1151 | 0.260 |
Why?
|
| Family | 4 | 2015 | 3144 | 0.260 |
Why?
|
| Government Programs | 3 | 2019 | 275 | 0.260 |
Why?
|
| Pyrrolidines | 2 | 1999 | 341 | 0.260 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 1999 | 503 | 0.250 |
Why?
|
| Acidosis, Lactic | 1 | 2006 | 142 | 0.250 |
Why?
|
| World Health Organization | 3 | 2022 | 1317 | 0.240 |
Why?
|
| Health Facilities | 2 | 2022 | 572 | 0.240 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2011 | 2027 | 0.240 |
Why?
|
| Family Characteristics | 1 | 2009 | 1000 | 0.240 |
Why?
|
| Drug Approval | 1 | 2010 | 742 | 0.230 |
Why?
|
| Hypertension | 1 | 2024 | 8480 | 0.230 |
Why?
|
| Receptors, Dopamine D1 | 2 | 1996 | 291 | 0.230 |
Why?
|
| Gram-Positive Bacteria | 1 | 2004 | 185 | 0.230 |
Why?
|
| Medical Records Systems, Computerized | 3 | 2004 | 1204 | 0.230 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 522 | 0.220 |
Why?
|
| Clorgyline | 2 | 1999 | 14 | 0.220 |
Why?
|
| Benzazepines | 2 | 1996 | 326 | 0.220 |
Why?
|
| Chlamydia Infections | 1 | 2006 | 365 | 0.210 |
Why?
|
| Vulnerable Populations | 3 | 2017 | 685 | 0.210 |
Why?
|
| Sexual Partners | 4 | 2010 | 728 | 0.210 |
Why?
|
| Violence | 1 | 2008 | 909 | 0.210 |
Why?
|
| Social Stigma | 3 | 2014 | 701 | 0.200 |
Why?
|
| Organizational Case Studies | 3 | 2020 | 299 | 0.200 |
Why?
|
| Gonorrhea | 1 | 2006 | 335 | 0.200 |
Why?
|
| Depressive Disorder | 2 | 2017 | 3744 | 0.200 |
Why?
|
| Benzamides | 2 | 1999 | 1383 | 0.200 |
Why?
|
| Women's Health | 1 | 2011 | 2033 | 0.200 |
Why?
|
| Medically Underserved Area | 1 | 2003 | 252 | 0.200 |
Why?
|
| Rats, Sprague-Dawley | 12 | 1999 | 8300 | 0.190 |
Why?
|
| Patient Compliance | 4 | 2012 | 2683 | 0.180 |
Why?
|
| National Health Programs | 2 | 2019 | 445 | 0.180 |
Why?
|
| Dextroamphetamine | 2 | 1997 | 129 | 0.180 |
Why?
|
| Health Resources | 2 | 2003 | 912 | 0.180 |
Why?
|
| Students | 1 | 2009 | 1647 | 0.180 |
Why?
|
| Malawi | 4 | 2023 | 282 | 0.170 |
Why?
|
| Depression | 5 | 2017 | 7760 | 0.170 |
Why?
|
| Quality of Life | 1 | 2021 | 12788 | 0.170 |
Why?
|
| Radiopharmaceuticals | 2 | 1999 | 2647 | 0.170 |
Why?
|
| Health Promotion | 2 | 2011 | 2205 | 0.170 |
Why?
|
| Maternal Mortality | 2 | 2012 | 310 | 0.170 |
Why?
|
| Financing, Organized | 1 | 2020 | 202 | 0.160 |
Why?
|
| Health Services Administration | 2 | 2017 | 64 | 0.160 |
Why?
|
| Uridine Monophosphate | 1 | 2018 | 70 | 0.160 |
Why?
|
| Earthquakes | 1 | 2021 | 179 | 0.160 |
Why?
|
| Disease Outbreaks | 4 | 2022 | 1771 | 0.160 |
Why?
|
| Female | 47 | 2023 | 380020 | 0.160 |
Why?
|
| Propylamines | 1 | 1999 | 165 | 0.160 |
Why?
|
| Peru | 6 | 2008 | 882 | 0.160 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 2 | 2008 | 92 | 0.150 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 1411 | 0.150 |
Why?
|
| Fluorenes | 1 | 2018 | 160 | 0.150 |
Why?
|
| Health Policy | 5 | 2014 | 2662 | 0.150 |
Why?
|
| Consumer Advocacy | 2 | 2011 | 81 | 0.150 |
Why?
|
| Socioeconomic Factors | 3 | 2010 | 7784 | 0.150 |
Why?
|
| Medical Informatics | 1 | 2004 | 745 | 0.150 |
Why?
|
| Parents | 2 | 2015 | 3403 | 0.150 |
Why?
|
| Point-of-Care Systems | 1 | 2006 | 1177 | 0.150 |
Why?
|
| House Calls | 1 | 2018 | 162 | 0.150 |
Why?
|
| Drug Costs | 2 | 2004 | 1105 | 0.140 |
Why?
|
| Brain | 10 | 1999 | 26345 | 0.140 |
Why?
|
| Social Responsibility | 1 | 2020 | 388 | 0.140 |
Why?
|
| Liberia | 1 | 2016 | 167 | 0.140 |
Why?
|
| Salicylamides | 1 | 1996 | 33 | 0.140 |
Why?
|
| Program Development | 3 | 2014 | 1314 | 0.130 |
Why?
|
| Pregnancy | 8 | 2023 | 29140 | 0.130 |
Why?
|
| Rats | 12 | 1999 | 24250 | 0.130 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 2291 | 0.130 |
Why?
|
| Antiviral Agents | 2 | 2018 | 2984 | 0.130 |
Why?
|
| Fees and Charges | 1 | 2016 | 195 | 0.130 |
Why?
|
| Financing, Government | 1 | 2019 | 469 | 0.130 |
Why?
|
| Pandemics | 4 | 2022 | 8385 | 0.130 |
Why?
|
| Rape | 2 | 2007 | 133 | 0.130 |
Why?
|
| Program Evaluation | 7 | 2018 | 2483 | 0.130 |
Why?
|
| Parent-Child Relations | 2 | 2010 | 746 | 0.130 |
Why?
|
| United Nations | 3 | 2011 | 165 | 0.130 |
Why?
|
| Binding, Competitive | 4 | 1998 | 1157 | 0.130 |
Why?
|
| Education, Nursing, Diploma Programs | 1 | 2014 | 11 | 0.130 |
Why?
|
| Radioligand Assay | 4 | 1999 | 374 | 0.120 |
Why?
|
| Malnutrition | 1 | 2021 | 625 | 0.120 |
Why?
|
| Population Dynamics | 1 | 2016 | 302 | 0.120 |
Why?
|
| Social Medicine | 1 | 2015 | 62 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 2 | 2007 | 251 | 0.120 |
Why?
|
| Male | 45 | 2018 | 349776 | 0.120 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 25032 | 0.120 |
Why?
|
| Macaca mulatta | 7 | 1999 | 2375 | 0.120 |
Why?
|
| Politics | 1 | 2021 | 791 | 0.120 |
Why?
|
| Mali | 1 | 2013 | 44 | 0.120 |
Why?
|
| Tissue Distribution | 5 | 1999 | 2327 | 0.120 |
Why?
|
| Retrospective Studies | 18 | 2024 | 77410 | 0.120 |
Why?
|
| Autoradiography | 3 | 1999 | 745 | 0.120 |
Why?
|
| Ebolavirus | 1 | 2016 | 260 | 0.120 |
Why?
|
| Adaptation, Psychological | 3 | 2015 | 2575 | 0.120 |
Why?
|
| Critical Illness | 2 | 2023 | 2670 | 0.120 |
Why?
|
| Health Care Reform | 1 | 2023 | 1261 | 0.120 |
Why?
|
| Quality Improvement | 2 | 2023 | 3750 | 0.110 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 392 | 0.110 |
Why?
|
| Corpus Striatum | 2 | 1999 | 1219 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2018 | 850 | 0.110 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 121 | 0.110 |
Why?
|
| Intensive Care Units | 2 | 2023 | 3679 | 0.110 |
Why?
|
| Adult | 29 | 2021 | 213889 | 0.110 |
Why?
|
| Learning | 1 | 2022 | 1710 | 0.110 |
Why?
|
| Internal-External Control | 1 | 2015 | 363 | 0.110 |
Why?
|
| Uganda | 2 | 2008 | 1237 | 0.110 |
Why?
|
| Nurse Midwives | 1 | 2012 | 24 | 0.110 |
Why?
|
| Hospitals | 2 | 2023 | 3953 | 0.110 |
Why?
|
| Health Services Research | 2 | 2017 | 1836 | 0.110 |
Why?
|
| Education, Nursing | 1 | 2012 | 82 | 0.100 |
Why?
|
| Personnel, Hospital | 1 | 2014 | 283 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2009 | 4266 | 0.100 |
Why?
|
| Qualitative Research | 5 | 2023 | 2682 | 0.100 |
Why?
|
| HIV Seronegativity | 2 | 2010 | 211 | 0.100 |
Why?
|
| Glycemic Index | 1 | 2014 | 394 | 0.100 |
Why?
|
| Inservice Training | 1 | 2014 | 392 | 0.100 |
Why?
|
| Child, Orphaned | 1 | 2012 | 55 | 0.100 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 127 | 0.100 |
Why?
|
| Healthy People Programs | 1 | 2011 | 53 | 0.100 |
Why?
|
| Midwifery | 1 | 2012 | 132 | 0.100 |
Why?
|
| Mother-Child Relations | 1 | 2014 | 481 | 0.090 |
Why?
|
| Curriculum | 2 | 2021 | 3603 | 0.090 |
Why?
|
| Viral Load | 6 | 2018 | 3300 | 0.090 |
Why?
|
| Epidemics | 1 | 2016 | 523 | 0.090 |
Why?
|
| Self-Help Groups | 1 | 2012 | 190 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2014 | 436 | 0.090 |
Why?
|
| Child, Preschool | 8 | 2022 | 40964 | 0.090 |
Why?
|
| Therapeutic Human Experimentation | 1 | 2010 | 43 | 0.090 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 1029 | 0.090 |
Why?
|
| Child Development | 1 | 2022 | 2212 | 0.090 |
Why?
|
| Occupations | 2 | 2010 | 517 | 0.090 |
Why?
|
| Research Design | 1 | 2006 | 5983 | 0.090 |
Why?
|
| Adolescent | 15 | 2017 | 85729 | 0.090 |
Why?
|
| Risk Factors | 8 | 2021 | 72252 | 0.090 |
Why?
|
| Russia | 5 | 2008 | 408 | 0.090 |
Why?
|
| Infant | 6 | 2022 | 35122 | 0.090 |
Why?
|
| Child Welfare | 1 | 2013 | 523 | 0.090 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2004 | 564 | 0.080 |
Why?
|
| Treatment Outcome | 14 | 2018 | 63042 | 0.080 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 3155 | 0.080 |
Why?
|
| Meningitis | 1 | 2010 | 216 | 0.080 |
Why?
|
| Africa | 2 | 2016 | 672 | 0.080 |
Why?
|
| Pilot Projects | 4 | 2015 | 8316 | 0.080 |
Why?
|
| Mexico | 2 | 2023 | 689 | 0.080 |
Why?
|
| Prevalence | 4 | 2021 | 15211 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2018 | 2560 | 0.080 |
Why?
|
| Schools, Medical | 1 | 2015 | 879 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2010 | 308 | 0.080 |
Why?
|
| Patient Dropouts | 2 | 2012 | 420 | 0.080 |
Why?
|
| Psychology | 1 | 2010 | 356 | 0.080 |
Why?
|
| Communicable Diseases | 1 | 2016 | 880 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 7908 | 0.080 |
Why?
|
| Skull | 1 | 1992 | 812 | 0.080 |
Why?
|
| Psychometrics | 1 | 2017 | 3000 | 0.080 |
Why?
|
| Mentors | 1 | 2012 | 631 | 0.080 |
Why?
|
| Nigeria | 1 | 2010 | 733 | 0.080 |
Why?
|
| Social Conditions | 1 | 2008 | 126 | 0.070 |
Why?
|
| Child | 11 | 2022 | 77637 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 1676 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 1859 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2017 | 1591 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 1077 | 0.070 |
Why?
|
| Disease Management | 1 | 2017 | 2459 | 0.070 |
Why?
|
| Health Status | 1 | 2020 | 4031 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 7172 | 0.070 |
Why?
|
| HIV-1 | 5 | 2010 | 6939 | 0.070 |
Why?
|
| Boston | 3 | 2009 | 9310 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2010 | 705 | 0.070 |
Why?
|
| Dopamine Antagonists | 2 | 1997 | 296 | 0.070 |
Why?
|
| Goals | 1 | 2011 | 708 | 0.070 |
Why?
|
| Algorithms | 1 | 2006 | 13869 | 0.070 |
Why?
|
| Conflict of Interest | 1 | 2010 | 544 | 0.070 |
Why?
|
| Obstetrics | 1 | 2012 | 657 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2012 | 906 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 5752 | 0.060 |
Why?
|
| Capacity Building | 2 | 2020 | 248 | 0.060 |
Why?
|
| Haloperidol | 2 | 1997 | 397 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2012 | 1092 | 0.060 |
Why?
|
| Marine Biology | 1 | 2004 | 18 | 0.060 |
Why?
|
| Focus Groups | 2 | 2023 | 1320 | 0.060 |
Why?
|
| Health Services | 1 | 2010 | 758 | 0.060 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2009 | 482 | 0.060 |
Why?
|
| Organizations | 2 | 2016 | 170 | 0.060 |
Why?
|
| Fetus | 1 | 1992 | 1880 | 0.060 |
Why?
|
| Cholera | 1 | 2011 | 785 | 0.060 |
Why?
|
| Counseling | 2 | 2010 | 1523 | 0.060 |
Why?
|
| Retreatment | 1 | 2006 | 609 | 0.060 |
Why?
|
| Residence Characteristics | 2 | 2015 | 2050 | 0.060 |
Why?
|
| Drug Industry | 1 | 2010 | 746 | 0.060 |
Why?
|
| Seawater | 1 | 2004 | 121 | 0.060 |
Why?
|
| Fertility | 1 | 2009 | 779 | 0.060 |
Why?
|
| Mothers | 1 | 2014 | 2166 | 0.060 |
Why?
|
| Netherlands | 1 | 2008 | 2170 | 0.060 |
Why?
|
| Professional Role | 1 | 2007 | 306 | 0.060 |
Why?
|
| Informed Consent | 1 | 2010 | 995 | 0.060 |
Why?
|
| General Surgery | 1 | 2015 | 1636 | 0.060 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 1911 | 0.060 |
Why?
|
| Thailand | 1 | 2004 | 299 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2009 | 986 | 0.060 |
Why?
|
| Disease Transmission, Infectious | 1 | 2009 | 546 | 0.060 |
Why?
|
| Drug Therapy, Combination | 4 | 2008 | 6487 | 0.060 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2004 | 103 | 0.060 |
Why?
|
| Patient Rights | 1 | 2004 | 126 | 0.060 |
Why?
|
| Education, Medical | 1 | 2015 | 1722 | 0.060 |
Why?
|
| Infant, Newborn | 4 | 2011 | 25609 | 0.050 |
Why?
|
| Social Change | 1 | 2003 | 153 | 0.050 |
Why?
|
| Weight Loss | 1 | 2014 | 2625 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2017 | 10251 | 0.050 |
Why?
|
| Prisoners | 1 | 2006 | 297 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 971 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 3020 | 0.050 |
Why?
|
| Middle Aged | 15 | 2021 | 213241 | 0.050 |
Why?
|
| Social Environment | 1 | 2007 | 1022 | 0.050 |
Why?
|
| Anthropology, Cultural | 1 | 2022 | 99 | 0.050 |
Why?
|
| Interpersonal Relations | 1 | 2009 | 1424 | 0.050 |
Why?
|
| Health Personnel | 3 | 2022 | 3217 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3134 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 2794 | 0.050 |
Why?
|
| Students, Medical | 1 | 2015 | 1862 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
| Civil Rights | 1 | 2022 | 132 | 0.050 |
Why?
|
| Linear Models | 1 | 2012 | 5952 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2003 | 376 | 0.050 |
Why?
|
| Jordan | 1 | 2021 | 74 | 0.050 |
Why?
|
| Antipsychotic Agents | 1 | 1995 | 3057 | 0.050 |
Why?
|
| Young Adult | 8 | 2017 | 56392 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2004 | 860 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2009 | 1338 | 0.050 |
Why?
|
| Middle East | 1 | 2021 | 219 | 0.050 |
Why?
|
| Commerce | 1 | 2006 | 592 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2004 | 954 | 0.050 |
Why?
|
| Animals | 14 | 1999 | 168660 | 0.050 |
Why?
|
| Logistic Models | 3 | 2012 | 13404 | 0.050 |
Why?
|
| Critical Care | 2 | 2023 | 2647 | 0.050 |
Why?
|
| Hepacivirus | 2 | 2018 | 1378 | 0.050 |
Why?
|
| Pediatrics | 1 | 2015 | 3474 | 0.050 |
Why?
|
| Selegiline | 1 | 1999 | 31 | 0.040 |
Why?
|
| Kinetics | 2 | 1999 | 6476 | 0.040 |
Why?
|
| Anxiety | 2 | 2015 | 4288 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2004 | 763 | 0.040 |
Why?
|
| Information Systems | 1 | 2002 | 410 | 0.040 |
Why?
|
| RNA, Viral | 3 | 2018 | 2901 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2004 | 1463 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 39001 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2004 | 820 | 0.040 |
Why?
|
| Canada | 1 | 2004 | 2064 | 0.040 |
Why?
|
| Receptors, Dopamine D3 | 1 | 1999 | 110 | 0.040 |
Why?
|
| Synaptosomes | 1 | 1998 | 115 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5078 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2007 | 941 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2012 | 9139 | 0.040 |
Why?
|
| Culture Techniques | 1 | 1998 | 553 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2004 | 1459 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2003 | 1680 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 1998 | 545 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2014 | 2538 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 418 | 0.040 |
Why?
|
| Patients | 1 | 2023 | 899 | 0.040 |
Why?
|
| Phylogeny | 1 | 2004 | 2796 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 14714 | 0.040 |
Why?
|
| AIDS Vaccines | 1 | 2003 | 938 | 0.040 |
Why?
|
| Cohort Studies | 6 | 2014 | 40545 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2001 | 1821 | 0.040 |
Why?
|
| Phencyclidine | 1 | 1996 | 61 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2022 | 21733 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 1422 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2006 | 6457 | 0.030 |
Why?
|
| Travel | 1 | 2022 | 788 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 593 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2004 | 1453 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 10259 | 0.030 |
Why?
|
| Macaca | 1 | 1997 | 439 | 0.030 |
Why?
|
| Raclopride | 1 | 1996 | 97 | 0.030 |
Why?
|
| Cebus | 1 | 1995 | 16 | 0.030 |
Why?
|
| Receptors, Serotonin | 1 | 1996 | 201 | 0.030 |
Why?
|
| Data Collection | 1 | 2004 | 3339 | 0.030 |
Why?
|
| Radioactive Tracers | 1 | 1995 | 72 | 0.030 |
Why?
|
| Internet | 2 | 2004 | 3058 | 0.030 |
Why?
|
| Disasters | 1 | 2021 | 511 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2021 | 1532 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 1998 | 982 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 4 | 2008 | 1832 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 1608 | 0.030 |
Why?
|
| Needlestick Injuries | 1 | 1994 | 67 | 0.030 |
Why?
|
| Electric Injuries | 1 | 1994 | 26 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 1996 | 577 | 0.030 |
Why?
|
| Fluconazole | 1 | 1994 | 146 | 0.030 |
Why?
|
| Cryptococcosis | 1 | 1994 | 101 | 0.030 |
Why?
|
| Molecular Structure | 2 | 1996 | 1894 | 0.030 |
Why?
|
| Health Education | 1 | 2020 | 1056 | 0.030 |
Why?
|
| Government Agencies | 1 | 2014 | 156 | 0.030 |
Why?
|
| Aged | 10 | 2018 | 163178 | 0.030 |
Why?
|
| Time Factors | 4 | 2013 | 40038 | 0.030 |
Why?
|
| Accidents | 1 | 1994 | 164 | 0.030 |
Why?
|
| Hospitals, Rural | 1 | 2015 | 172 | 0.030 |
Why?
|
| Nepal | 1 | 2014 | 295 | 0.030 |
Why?
|
| Organ Specificity | 1 | 1998 | 2008 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2001 | 1899 | 0.030 |
Why?
|
| Sputum | 2 | 2008 | 476 | 0.030 |
Why?
|
| Teaching | 1 | 2021 | 1173 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 205 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 1996 | 3128 | 0.030 |
Why?
|
| HIV Seroprevalence | 1 | 2012 | 86 | 0.030 |
Why?
|
| Calcium Channels | 1 | 1996 | 622 | 0.030 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2014 | 340 | 0.030 |
Why?
|
| Thiazoles | 1 | 1999 | 1482 | 0.030 |
Why?
|
| Incidence | 2 | 2011 | 20948 | 0.030 |
Why?
|
| Heart Failure | 1 | 2016 | 10896 | 0.030 |
Why?
|
| Ligands | 1 | 1999 | 3281 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1995 | 1574 | 0.020 |
Why?
|
| Transfection | 1 | 1999 | 5892 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 2014 | 346 | 0.020 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1996 | 896 | 0.020 |
Why?
|
| Twins | 1 | 1992 | 339 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 11729 | 0.020 |
Why?
|
| Inpatients | 1 | 2022 | 2515 | 0.020 |
Why?
|
| Fetal Death | 1 | 1992 | 448 | 0.020 |
Why?
|
| Dopamine | 1 | 1997 | 1592 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 601 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2003 | 3207 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2022 | 53250 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 6620 | 0.020 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 13980 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1994 | 1108 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 5388 | 0.020 |
Why?
|
| Cerebellum | 1 | 1996 | 1487 | 0.020 |
Why?
|
| Physician Incentive Plans | 1 | 2009 | 161 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1796 | 0.020 |
Why?
|
| Mass Screening | 1 | 2023 | 5251 | 0.020 |
Why?
|
| Social Isolation | 1 | 2010 | 367 | 0.020 |
Why?
|
| Latvia | 1 | 2006 | 14 | 0.020 |
Why?
|
| Estonia | 1 | 2006 | 53 | 0.020 |
Why?
|
| Philippines | 1 | 2006 | 86 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2003 | 1870 | 0.020 |
Why?
|
| Radiography | 1 | 1997 | 7010 | 0.020 |
Why?
|
| Fear | 1 | 2014 | 1438 | 0.020 |
Why?
|
| United States | 3 | 2021 | 69859 | 0.020 |
Why?
|
| Mitochondria | 1 | 1998 | 3513 | 0.020 |
Why?
|
| Leadership | 1 | 2014 | 1357 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 10940 | 0.020 |
Why?
|
| Cell Line | 1 | 1999 | 15993 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 1917 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2006 | 23327 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2017 | 2492 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2009 | 725 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2007 | 469 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2017 | 2348 | 0.010 |
Why?
|
| Epitopes | 2 | 2001 | 2570 | 0.010 |
Why?
|
| Genotype | 1 | 2018 | 12944 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2013 | 6356 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2760 | 0.010 |
Why?
|
| Perception | 1 | 2010 | 1198 | 0.010 |
Why?
|
| Body Weight | 1 | 2014 | 4670 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 1503 | 0.010 |
Why?
|
| Risk | 1 | 2015 | 9677 | 0.010 |
Why?
|
| Length of Stay | 1 | 2016 | 6311 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2016 | 5316 | 0.010 |
Why?
|
| Information Management | 1 | 2002 | 101 | 0.010 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2003 | 271 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1997 | 8939 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 2001 | 213 | 0.010 |
Why?
|
| Gene Products, gag | 1 | 2001 | 337 | 0.010 |
Why?
|
| Acute Disease | 2 | 2001 | 7150 | 0.010 |
Why?
|
| HIV Antigens | 1 | 2001 | 347 | 0.010 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 222 | 0.010 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 1070 | 0.010 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2005 | 623 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 13809 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 19894 | 0.010 |
Why?
|
| Public Health Practice | 1 | 2001 | 217 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 4931 | 0.010 |
Why?
|
| Comorbidity | 1 | 2012 | 10380 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2008 | 2707 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2007 | 1438 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 2891 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8637 | 0.010 |
Why?
|
| Dizocilpine Maleate | 1 | 1996 | 176 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2002 | 953 | 0.010 |
Why?
|
| Genetic Variation | 2 | 2001 | 6535 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1996 | 462 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2001 | 985 | 0.010 |
Why?
|
| Isotope Labeling | 1 | 1996 | 405 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 1994 | 137 | 0.010 |
Why?
|
| Research | 1 | 2002 | 1999 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 12354 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12243 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 3608 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12798 | 0.010 |
Why?
|
| Muscles | 1 | 1994 | 1613 | 0.010 |
Why?
|
| Smoking | 1 | 2006 | 8984 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 18355 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 18107 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 57744 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1996 | 3758 | 0.000 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 7270 | 0.000 |
Why?
|